These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24811892)

  • 1. NICE's cost-effectiveness range: should it be lowered?
    Raftery JP
    Pharmacoeconomics; 2014 Jul; 32(7):613-5. PubMed ID: 24811892
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE's cost effectiveness threshold.
    Appleby J; Devlin N; Parkin D
    BMJ; 2007 Aug; 335(7616):358-9. PubMed ID: 17717337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crossing the line: NICE's value for money threshold.
    Appleby J
    BMJ; 2016 Mar; 352():i1336. PubMed ID: 26960807
    [No Abstract]   [Full Text] [Related]  

  • 5. Should NICE's threshold range for cost per QALY be raised? No.
    Raftery J
    BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562
    [No Abstract]   [Full Text] [Related]  

  • 6. Should NICE's threshold range for cost per QALY be raised? Yes.
    Towse A
    BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
    [No Abstract]   [Full Text] [Related]  

  • 7. Review of NICE's recommendations, 1999-2005.
    Raftery J
    BMJ; 2006 May; 332(7552):1266-8. PubMed ID: 16735341
    [No Abstract]   [Full Text] [Related]  

  • 8. Protest over end of NICE's project on safe staffing.
    Nurs Stand; 2015 Jun; 29(43):9. PubMed ID: 26103832
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 10. Interpretation of cost-effectiveness analyses.
    Owens DK
    J Gen Intern Med; 1998 Oct; 13(10):716-7. PubMed ID: 9798822
    [No Abstract]   [Full Text] [Related]  

  • 11. Experts disagree over NICE's approach for assessing drugs.
    Hoey R
    Lancet; 2007 Aug; 370(9588):643-4. PubMed ID: 17726791
    [No Abstract]   [Full Text] [Related]  

  • 12. A NICE fallacy.
    Quigley M
    J Med Ethics; 2007 Aug; 33(8):465-6. PubMed ID: 17664304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is NICE ageist? Highlights from this issue.
    Douglas T
    J Med Ethics; 2012 May; 38(5):257. PubMed ID: 22518054
    [No Abstract]   [Full Text] [Related]  

  • 14. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
    O'Mahony JF; Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics: NICE's approach to decision-making.
    Rawlins M; Barnett D; Stevens A
    Br J Clin Pharmacol; 2010 Sep; 70(3):346-9. PubMed ID: 20716233
    [No Abstract]   [Full Text] [Related]  

  • 17. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

  • 19. NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?
    Sculpher M
    Pharmacoeconomics; 2008; 26(9):721-4. PubMed ID: 18767891
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis 2.0.
    Neumann PJ; Sanders GD
    N Engl J Med; 2017 Jan; 376(3):203-205. PubMed ID: 28099837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.